We have developed a proprietary computational approach that uses in-silico therapeutic discovery and molecular design to improve upon traditional biotechnology. This makes up our iPlatform™ and this is TechBio, the future of biopharma.
This creates both economic and time-saving advantages to drug discovery, allowing for life-saving solutions to potentially reach the clinic faster and more affordably.
Develops drugs with wide range applications
Delivers highly effective and functional treatments
Creates safer drugs in less time at less cost
Partnership with Amazon Web Services
The development of iPlatform™ is supported in part through a partnership agreement with Amazon Web Services (AWS) to aid in the development of its proprietary iPlatform™ technology.
iPlatform™ Therapeutic Pipeline
iMBP has five established disease therapeutic asset programs, with four additional programs in preparation to go online. We're also proud to announce our issued U.S. patent for proprietary therapeutic methodology (US/9,783,600).
Our TechBio approach has allowed iMBP to achieve multiple milestones normally not experienced in BioTech companies until much later in life.
This has been significantly enabled through two partnership agreements with Ligand Pharmaceuticals/OmniAb for drug asset development.
“Ligand is proud of its heritage of establishing strategic partnerships with innovative, emerging organizations with experienced management teams, and our agreement with iMetabolic Biopharma Corporation is another example of such an alliance”
John Higgins - Former CEO at Ligand Pharmaceuticals